Charles River Laboratories International, Inc. $CRL Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 98.4% during the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 2,454 shares of the medical research company’s stock after selling 151,431 shares during the period. Pacer Advisors Inc.’s holdings in Charles River Laboratories International were worth $423,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of CRL. NewEdge Advisors LLC grew its stake in Charles River Laboratories International by 1,119.5% in the 1st quarter. NewEdge Advisors LLC now owns 3,195 shares of the medical research company’s stock worth $551,000 after acquiring an additional 2,933 shares during the period. Avidity Partners Management LP purchased a new position in shares of Charles River Laboratories International during the 1st quarter worth $1,670,000. Glenmede Trust Co. NA lifted its stake in shares of Charles River Laboratories International by 2.8% during the 1st quarter. Glenmede Trust Co. NA now owns 2,706 shares of the medical research company’s stock worth $467,000 after purchasing an additional 73 shares during the period. Bank of America Corp DE boosted its holdings in shares of Charles River Laboratories International by 5.0% during the first quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after purchasing an additional 54,500 shares during the last quarter. Finally, Edgestream Partners L.P. acquired a new stake in shares of Charles River Laboratories International during the first quarter worth $1,559,000. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, CAO Michael Gunnar Knell sold 6,645 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the sale, the chief accounting officer owned 11,852 shares in the company, valued at approximately $3,086,023.76. The trade was a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Victoria L. Creamer sold 4,179 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the sale, the executive vice president directly owned 30,051 shares of the company’s stock, valued at approximately $7,788,017.16. This trade represents a 12.21% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 119,603 shares of company stock valued at $28,916,928. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International News Summary

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Analyst support remains favorable. Piper Sandler set a $300 price target, while Barclays maintained an overweight rating and a $300 target. RBC also raised its target to $282 and reiterated an outperform rating. Overall, 12 analysts rate CRL a Buy, three recommend Hold and one recommends Sell, producing a consensus “Moderate Buy” rating. Charles River Laboratories International Given Consensus Rating of Moderate Buy
• Positive Sentiment: Recent operating results exceeded expectations. Charles River reported quarterly adjusted earnings of $3.02 per share versus the $2.77 consensus estimate, while revenue of approximately $1.0 billion topped expectations of $980.5 million. Fiscal 2026 earnings guidance remains $11.15 to $11.45 per share.
• Positive Sentiment: Strong momentum has attracted attention. CRL reached a new 52-week high near $277, with trading volume above its average. The stock is also well above its 50-day and 200-day moving averages, indicating continued technical momentum. Charles River Laboratories International Sets New 52-Week High
• Neutral Sentiment: International-market exposure remains an investor focus. A recent analysis examines how Charles River’s international revenue trends could affect Wall Street forecasts and the stock’s outlook, but the provided report does not identify a specific estimate change. International Markets and Charles River Deep Dive
• Negative Sentiment: Several insiders sold shares. Director James C. Foster sold 28,733 shares for approximately $7.9 million under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 47.6%. EVP Victoria Creamer sold 4,179 shares worth about $1.1 million, and CAO Michael Gunnar Knell sold 6,645 shares worth approximately $1.7 million. These planned transactions may raise caution, although they do not necessarily signal deteriorating business prospects. SEC insider transaction filing

Wall Street Analyst Weigh In

Several research firms recently commented on CRL. Robert W. Baird set a $291.00 target price on Charles River Laboratories International in a research note on Thursday, August 6th. CLSA lowered Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research note on Monday, July 20th. BNP Paribas Exane set a $250.00 price target on Charles River Laboratories International in a report on Wednesday, July 1st. TD Cowen upped their price objective on shares of Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research note on Monday. Finally, Royal Bank Of Canada increased their price objective on shares of Charles River Laboratories International from $215.00 to $282.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $255.65.

Charles River Laboratories International Trading Up 1.7%

CRL stock opened at $281.70 on Wednesday. The company has a market cap of $13.45 billion, a price-to-earnings ratio of -58.08, a PEG ratio of 2.87 and a beta of 1.38. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.92. The business has a fifty day simple moving average of $218.88 and a 200-day simple moving average of $189.84. Charles River Laboratories International, Inc. has a 52 week low of $144.26 and a 52 week high of $282.39.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The business had revenue of $1 billion for the quarter, compared to analyst estimates of $980.53 million. During the same period last year, the company posted $3.12 EPS. The business’s quarterly revenue was down 2.7% on a year-over-year basis. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, equities research analysts expect that Charles River Laboratories International, Inc. will post 11.34 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.